eFFECTOR Therapeutics Initiates Phase 1/2 Safety and Efficacy Study of Zotatifin (eFT226) in Patients with Advanced Solid Tumor Malignancies

Frank Burrell
Scientific Storytelling

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing